Heat Therapy With Radiation or Chemoradiation for Bladder Cancer
Tests heat treatment added to radiation or chemoradiation in adults with bladder cancer.
Plain-language title generated from the registry record
Registry title: Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia
Key facts
- Where
- Erlangen, GermanySee the site
Where in Germany
- Dept. of Radiation Therapy, University Hospital ErlangenErlangen, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Erlangen-Nürnberg Medical School
- Trial code
- NCT05397262
- Record updated
- 9 May 2024
- Original description
Analysis of the efficacy and the compatibility of deep regional hyperthermia in combination with radiotherapy and chemoradiotherapy in bladder cancerRead full original descriptionShow less
Register-Trial Based on an Agreement of Health Insurances With the Department of Radiation Therapy of the University Hospital Erlangen for the Application of Regional Hyperthermia in Bladder Cancer: Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia
Analysis of the efficacy and the compatibility of deep regional hyperthermia in combination with radiotherapy and chemoradiotherapy in bladder cancer
Inclusion: Age ≥ 18 years; Histologically confirmed bladder cancer; M0; ECOG-performance status ≤ 2; Informed consent.
Exclusion: Metal implants (lenght > 2cm or dense clusters of marker clips in the pelvis); Patients not willing to use effective contraception during and up to 6 months after therapy; Pre-existing uncontrolled cardiac disease, signs of cardiac failure, or rhythm disturbances requiring therapy; Cardiac Pacemaker; Myocardial infarction within the past 12 months; Congestive heart failure; New York Heart Association (NYHA) class III or IV heart disease; Disease that would preclude TUR, chemoradiation or deep regional hyperthermia; Active or therapy-resistent bladder infections; Complete bundle branch block; Pre-existing or concommitant immunodeficiency Syndrom; Pregnant or lactating women.